Homology Medicines

BEDFORD, MA · Founded 2015 · CIK 0001661998 · Biotech · Acquired

proprietary AAV gene editing platform for rare genetic diseases using human hematopoietic stem cells

homologymedicines.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$107M
2 Form D · Aug 2017
110 months since last filing
Contracts
—
No federal contracts on record
Patents
40
8 granted · 32 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$23,068,876
Private capital raisedForm D · SEC$83,500,008
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2014SixPeaks Bio——
2015OSTREA BIO, INC.——
2016Crystalys——
2017Homology Medicines—$107M
2018Braveheart Bio——
2019Outer Biosciences, LLC—$4.0M
2020VITAKEY, INC.—$44M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 10 related persons
  • Steven GillisDirector
  • Richard GregoryDirector
  • Kush ParmarDirector · Executive Officer
  • Siyamak RastyExecutive Officer
  • Albert SeymourExecutive Officer
  • Mahendra ShahDirector
  • Brad SmithExecutive Officer
  • Paul StoneDirector · Executive Officer
  • Arthur TzianabosDirector · Executive Officer
  • Cameron WheelerDirector

Patents

USPTO · 8 granted of 40

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.